Bumrungrad Hospital PCL

Bumrungrad Hospital reported Q1 2026 EPS of $2.06 versus a $2.04 estimate and revenue of $6.2 billion (expectation $5.98 billion). EBITDA rose 5% and revenue from non-Thai patients increased 4.2%, while revenue from Thailand fell 3.6%. The share price fell 2.86% premarket to $170, pressured by declining domestic sales and longer receivable days (71.7 days). Management does not plan further price increases and is focusing on international expansion and growing outpatient and robot-assisted services. » Altro su de.investing.com

Bumrungrad Hospital reported Q1 2026 earnings per share of $2.06 (expectation $2.04) and revenue of $6.2 billion (forecast $5.98 billion). The EBITDA margin rose to a record high of 39.3%, driven by growth in non‑Thai patients, notably from the Middle East. Despite the stronger metrics, the share price fell 2.86% in premarket trading. The company plans capacity expansions (Phuket project, » Altro su de.investing.com

Bumrungrad Hospital PCL reported Q2 2025 revenue down 3.6% to THB 6,104 million, EBITDA of THB 2,537 million (-1.6%), and a record EBITDA margin of 41.6%; net profit fell 3.8% to THB 1,858 million with a near-stable net margin of 30.4%. The share of international patients dropped to 64%, international revenue declined 6.6%, while Middle East revenue rose sequentially versus Q1 (UAE +46%, Saudi Arabia +54%, Oman +28%). The company has a strong net cash position, is investing in robotics and specialty centers, and paid THB 2 per share in the first half with a 44% payout ratio. » Altro su de.investing.com